In order to investigate if the levels of different chemerin forms were being modified by ex vivo proteolytic processing, we determined the different chemerin forms in ascitic fluid from ovarian carcinoma patients in the absence or presence of protease inhibitors (Figure 3). Here, RARRES2 is linked to ovarian carcinoma.